lyophilized peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
This should in no way suggest to clinicians or researchers that inhaled particles are not a greater threat than swallowed particles, it merely signifies that a combination of both methods may occur with some particles, no matter the size of or lipo/hydrophilicity of the different particle surfaces.
The Leidenfrost point signifies the onset of stable film boiling. It represents the point on the boiling curve where the heat flux is at the minimum and the surface is completely covered by a vapor blanket. Heat transfer from the surface to the liquid occurs by conduction and radiation through the vapour. In 1756, Leidenfrost observed that water droplets supported by the vapor film slowly evaporate as they move about on the hot surface. As the surface temperature is increased, radiation through the vapor film becomes more significant and the heat flux increases with increasing excess temperature. The minimum heat flux for a large horizontal plate can be derived from Zuber's equation,
On June 30, 2009, the song "A Looking in View" was made available for purchase via iTunes and Amazon, and for a limited time it was available as a free download through the official Alice in Chains website in early July. Although it was not the album's first radio single, Rock stations across the U.S. started playing the song. The music video for "A Looking in View" debuted via the band's official website on July 7, 2009. The song was nominated for a Grammy Award for Best Hard Rock Performance. "Check My Brain" was released to radio stations as the first official single from the album on August 14, 2009, and was made available for purchase on August 17, 2009. The music video for "Check My Brain" premiered on September 14, 2009. The song was also nominated for a Grammy Award for Best Hard Rock Performance. To promote the album, the band released an EPK featuring all four of the members being interviewed while the Kiss makeup is being applied on them. An app for iPhone was released on October 27, 2009, featuring songs, music videos, news, photos and networking.
Sources: en.wikipedia.org
A band mask is a heavy duty full-face mask with many of the characteristics of a lightweight demand helmet. In structure it is the front section of a lightweight helmet from above the faceplate to below the demand valve and exhaust ports, including the bailout block and communications connections on the sides. This rigid frame is attached to a neoprene hood by a metal clamping band, hence the name. It is provided with a padded sealing surface around the frame edge which is held firmly against the diver's face by a rubber "spider", a multiple strap arrangement with a pad behind the diver's head, and usually five straps which hook onto pins on the band. The straps have several holes so the tension can be adjusted to get a comfortable seal. A band mask is heavier than other full face masks, but lighter than a helmet, and can be donned more quickly than a helmet. They are often used by the standby diver for this reason.
== Research interests == Among his many research interests, Hunt investigates how the immune system uses peptides to kill diseased cells, and how modifications to chromatin-associated proteins called histones create a "Code" that may be involved in many gene regulation events.
== Civilian career == After his retirement from the Air Force, Chain devoted himself full-time to corporate management. In March 1991 he became executive vice president for Burlington Northern Railroad, a position he held for five years. He was also special assistant to the chairman of that company in 1995 and 1996. In 1996 he became president of Quarterdeck Equity Partners, a subsidiary of Quarterdeck Investment Partners, Inc., a position he held until 2002. Chain became a member of the board of directors of Thomas Group, a management consulting company, in 1995, and was elevated to chairman of the board in 1998. He is also a director of RJ Reynolds, Inc., ConAgra Foods, Inc. and Kemper Insurance Co.. Chain's also serves as a board member of Northrop Grumman, one of the world's largest defense contractors. He gained this position in 1991 and oversaw the company's dramatic growth throughout the 1990s. John Chain was active in politics, though mostly behind the scenes. He was a Bush Pioneer in 2000, meaning that he gathered $100,000 for George W. Bush's 2000 presidential campaign. He was also a member of the Council on Foreign Relations. Chain died in his sleep at the age of 86 in July 2021.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.